# Phase 26 Closeout — Production-Path-Native Alpha Discovery & Validation

**Status:** **ACCEPTED_NEGATIVE — full phase-end gate PASS on target machine and exact-head Ubuntu/Windows CI.**  
**Frozen policy fingerprint:** `24e4f0e24d3e81dfc3dc572f0562337b2c156cd3ea22d6a7448b6ad6586016d2`

## Plain-English phase end

### Goal

Phase 26 had one central job: determine whether a preregistered set of genuinely different, production-path-native strategy ideas could establish reliable historical trading edge after realistic costs and strict anti-overfitting controls.

### What we built

ATLAS built an exact Phase25-production-path-native research population, a frozen 24-candidate library spanning six materially different strategy families, dependence-aware chronological selection/internal validation, global multiplicity control, finalist-only protected confirmation, independent persisted-artifact reconciliation, and a bounded end-to-end anti-workaround audit of the provider-to-execution authority path.

### Did the full phase gate pass?

**Yes. Phase 26 is ACCEPTED_NEGATIVE.**

The software, research process, independent validation, protected-blind behavior, architecture audit, target-machine closeout, and exact-head cross-platform CI all passed. The scientific result itself was negative: none of the 24 frozen candidates earned support.

### What the results mean

No candidate survived the development-selection standard. Because there were no selection survivors, there were no internal-validation finalists and no protected-confirmation candidates. Protected returns therefore remained completely unread, exactly as the methodology required.

This is not a software failure and it is not a reason to weaken the rules. It is valid negative scientific evidence. ATLAS still has no historically `SUPPORTED` strategy, so the existing signal-to-trade phase entry condition remains unsatisfied.

### What ATLAS can do now

The accepted data, analytics, identity, discovery, regime, ML probability, promoted-only research, trade-planning/risk, AI-audit, SHADOW/PAPER execution-safety, current-analysis, browser/API, and observability foundations remain intact. Phase 26 additionally proves that the first materially different production-path-native alpha library does **not** justify support under the frozen standard.

### What is still missing/risky

The primary missing requirement remains validated alpha. No strategy currently has accepted `SUPPORTED` authority. Therefore there is still no evidence basis for advancing into signal-to-trade optimization, full historical portfolio replay, prospective PAPER certification, or LIVE progression.

### Where this leaves the project

Phase 26 closes successfully as a negative research phase. Phase11 support remains unchanged at SUPPORTED 0 / MIXED 3 / UNSUPPORTED 5. Negative evidence grants no downstream trading authority.

### What happens next

The next numbered phase must be a separately preregistered alpha-research phase informed by the Phase 26 failure modes. The frozen Phase 26 candidates, thresholds, chronology, costs, and acceptance standards must not be tuned after seeing this result. The roadmap must be explicitly rebaselined before that next phase begins; the blocked signal-to-trade work is not entered merely to keep phase numbering moving.

## Research target evidence

Exact valid target-tested research head:

`8c9153c966ada116199fc45867bf5734efafeee4`

Target output:

- development usable observations: **21,483**;
- protected predictor observations: **1,096**;
- selection survivors: **0**;
- internal-validation finalists: **0**;
- protected-confirmed supported candidates: **0**;
- protected return rows read: **0**;
- independent validation: **PASS**;
- provider/broker/order/PAPER/LIVE activity: **0 / 0 / 0 / 0 / 0**;
- cumulative research evidence: **PASS**.

These row counts document the observed target evidence; they are not retrospective acceptance thresholds.

## Full target-machine closeout evidence

Exact target-tested closeout head:

`0c22889d0e8d33f19aab9ac405478255d990bdb6`

Command:

```powershell
.\.venv\Scripts\python.exe scripts\run_phase26_closeout.py
```

Observed closeout:

- Phase 26 closeout: **PASS**;
- disposition: **ACCEPTED_NEGATIVE**;
- selection survivors: **0**;
- internal-validation finalists: **0**;
- supported candidates: **0**;
- protected return rows read: **0**;
- end-to-end anti-workaround audit: **PASS**;
- Phase 27 entry satisfied: **False**;
- provider/broker/order/PAPER/LIVE activity: **0 / 0 / 0 / 0 / 0**;
- closeout report: `data/derived/strategy_evaluation/phase26/v1/phase26_closeout_report.json`;
- overall pass: **True**.

The closeout command did not rerun strategy search or read new protected performance. It bound the already-produced target artifacts to the full phase-end acceptance gate.

## Defects found and repaired before the valid target result

The final negative result was reached only after correcting implementation defects at their owning layers:

1. Phase 25 prerequisite recovery had accumulated redundant rebind/validator wrappers. The extra layer was removed and recovery returned to one authoritative recovery path plus the standard validator.
2. Phase 26 observation-report JSON persistence leaked NumPy/Pandas boolean scalars. The persistence boundary now requires native boolean checks and has regression coverage.
3. Phase 26 development research contained an impossible acceptance predicate (`protected_returns_read=False` inside an `all(checks.values())` map). The state/predicate confusion was removed and replaced by positive protected-blind invariants, with regression coverage.

No strategy definition, threshold, chronology, cost, bootstrap, multiplicity, robustness, or protected boundary was changed to obtain the final result.

## End-to-end anti-workaround audit

The required bounded audit is documented in `docs/phase26_end_to_end_anti_workaround_audit.md`.

Result: **PASS**. No acceptance-blocking workaround or parallel trading authority remains in the reviewed provider-to-execution critical path. Historical recovery code is bounded to provenance/rehydration and does not become routine promotion, risk, broker, PAPER, LIVE, or browser authority.

The closeout implementation machine-checks the highest-risk conclusions, including a single raw broker-submit seam, no runtime imports of Phase 25 recovery authority, no automatic broker failover, no current browser provider-write/LIVE endpoint, and unchanged zero-supported Phase 23 strategy authority.

## Cross-platform acceptance evidence

Exact-head GitHub Actions workflow:

`33043048986`

Head:

`0c22889d0e8d33f19aab9ac405478255d990bdb6`

Results:

- Ubuntu: **PASS**;
- Windows: **PASS**;
- retained Phase 3–25 validators: **PASS**;
- `Validate Phase 26 closeout and anti-workaround contracts`: **PASS** on both operating systems;
- full pytest regression suite: **PASS** on both operating systems.

## Final disposition

**Phase 26 is ACCEPTED_NEGATIVE.**

This acceptance means ATLAS trusts the negative conclusion. It does **not** create strategy support, broker authority, PAPER authority, LIVE authority, or permission to enter a downstream phase whose alpha entry condition is unsatisfied.
